SML2653

Sorafenib

≥98% (HPLC), powder, kinase inhibitor

• Synonym(s): 4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide, BAY 43-9006, BAY43-9006, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N′-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
• Empirical Formula (Hill Notation): C₂₁H₁₆ClF₃N₄O₃
• CAS Number: 284461-73-0
• Molecular Weight: 464.82
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD06411450
• Assay: ≥98% (HPLC)
• Form: powder

Properties

• Product Name: Sorafenib, ≥98% (HPLC)
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: FC(F)(F)c1c(ccc(c1)NC(=O)Nc2ccc(cc2)Oc3cc(ncc3)C(=O)NC)Cl
• InChI: 1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
• InChI key: MLDQJTXFUGDVEO-UHFFFAOYSA-N

Description

Biochem/physiol Actions

Sorafenib (BAY 43-9006) is an orally active kinase inhibitor that exerts broad-spectrum anticancer efficacy in vitro and in vivo via targeting b-Raf, c-Raf (Raf-1), as well as several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular endothelial growth factor receptors 2/3 (VEGFR-2/Flk-1/KDR, VEGFR-3), platelet-derived growth factor receptor-beta (PDGFR-β), Flt-3, c-KIT, FGFR-1 (Flt-2) and RET.

Safety Information

• pictograms: GHS08,GHS09
• signalword: Danger
• hcodes: H360FD,H362,H372,H410
• pcodes: P202 - P260 - P263 - P264 - P273 - P308 + P313
• Hazard Classifications: Aquatic Acute 1 - Aquatic Chronic 1 - Lact. - Repr. 1B - STOT RE 1
• Storage Class: 6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable